{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:11:58Z","timestamp":1794013918240,"version":"4.8.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA 000523-13"],"award-info":[{"award-number":["DA 000523-13"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA000606"],"award-info":[{"award-number":["DA000606"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ghent University Special Research Fund","award":["01J15517"],"award-info":[{"award-number":["01J15517"]}]},{"name":"Research Foundation-Flanders","award":["V434122N"],"award-info":[{"award-number":["V434122N"]}]},{"name":"FWO","award":["1S81522N"],"award-info":[{"award-number":["1S81522N"]}]},{"name":"FWO","award":["G069419N"],"award-info":[{"award-number":["G069419N"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00213-023-06451-2","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T10:01:50Z","timestamp":1693648910000},"page":"2573-2584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u2018nitazene\u2019 opioids associated with human overdose"],"prefix":"10.1007","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-9083","authenticated-orcid":false,"given":"Grant C.","family":"Glatfelter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe M.","family":"Vandeputte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Hua M.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe P.","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"6451_CR1","doi-asserted-by":"publisher","first-page":"i","DOI":"10.1017\/9781009182126","volume-title":"Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance","author":"D Abdulrahim","year":"2022","unstructured":"Abdulrahim D, Bowden-Jones O (2022) Textbook of clinical management of club drugs and novel psychoactive substances. In: Abdulrahim D, Bowden-Jones O (eds) Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances: NEPTUNE Clinical Guidance. Cambridge University Press, Cambridge, pp i\u2013ii"},{"key":"6451_CR2","first-page":"103","volume":"140","author":"MD Aceto","year":"1994","unstructured":"Aceto MD, Bowman ER, Harris LS, May EL (1994) Dependence studies of new compounds in the rhesus monkey, rat and mouse (1993). NIDA Res Monogr 140:103\u2013178","journal-title":"NIDA Res Monogr"},{"key":"6451_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30218-4","volume":"6","author":"Y Bao","year":"2019","unstructured":"Bao Y, Meng S, Shi J, Lu L (2019) Control of fentanyl-related substances in China. Lancet Psychiatry 6:e15. https:\/\/doi.org\/10.1016\/S2215-0366(19)30218-4","journal-title":"Lancet Psychiatry"},{"key":"6451_CR4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.tips.2018.09.006","volume":"39","author":"MH Baumann","year":"2018","unstructured":"Baumann MH, Kopajtic TA, Madras BK (2018) Pharmacological research as a key component in mitigating the opioid overdose crisis. Trends in Pharmacol Sci 39:995\u2013998. https:\/\/doi.org\/10.1016\/j.tips.2018.09.006","journal-title":"Trends in Pharmacol Sci"},{"key":"6451_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/dta.2738","volume":"12","author":"P Blanckaert","year":"2020","unstructured":"Blanckaert P, Cannaert A, Van Uytfanghe K, Hulpia F, Deconinck E, Van Calenbergh S, Stove C (2020) Report on a novel emerging class of highly potent benzimidazole NPS opioids: Chemical and in vitro functional characterization of isotonitazene. Drug Test Anal 12:422\u2013430. https:\/\/doi.org\/10.1002\/dta.2738","journal-title":"Drug Test Anal"},{"key":"6451_CR6","first-page":"31","volume":"70","author":"H Brandenberger","year":"1974","unstructured":"Brandenberger H (1974) Die Rolle des Massenspektrometers im toxikologisch-chemischen Laboratorium. Deutsche Lebensmittel-Rundschau 70:31\u201339","journal-title":"Deutsche Lebensmittel-Rundschau"},{"key":"6451_CR7","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI126912","volume":"129","author":"NS Cai","year":"2019","unstructured":"Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casado-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casado V et al (2019) Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids. J Clin Invest 129:2730\u20132744. https:\/\/doi.org\/10.1172\/JCI126912","journal-title":"J Clin Invest"},{"key":"6451_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109263","volume":"221","author":"MA De Luca","year":"2022","unstructured":"De Luca MA, Tocco G, Mostallino R, Laus A, Caria F, Musa A, Pintori N, Ucha M, Poza C, Ambrosio E, Di Chiara G, Castelli MP (2022) Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent mu-opioid receptor agonists. Neuropharmacology 221:109263. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109263","journal-title":"Neuropharmacology"},{"key":"6451_CR9","volume-title":"21 CFR Part 1308: Schedules of controlled substances: Temporary placement of butonitazene, etodesnitazene, flunitazene, metodesnitazene, metonitazene, N-pyrrolidino etonitazene, and protonitazene in schedule I","author":"DEA","year":"2021","unstructured":"DEA (2021) 21 CFR Part 1308: Schedules of controlled substances: Temporary placement of butonitazene, etodesnitazene, flunitazene, metodesnitazene, metonitazene, N-pyrrolidino etonitazene, and protonitazene in schedule I. Federal Register 86 https:\/\/www.govinfo.gov\/content\/pkg\/FR-2021-12-07\/pdf\/2021-26263.pdf"},{"key":"6451_CR10","volume-title":"EMCDDA technical report on the new psychoactive substance N,N-diethyl-2-((5-(1-methylethoxy)phenyl)methyl)-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene)","author":"EMCDDA","year":"2020","unstructured":"EMCDDA (2020) EMCDDA technical report on the new psychoactive substance N,N-diethyl-2-((5-(1-methylethoxy)phenyl)methyl)-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene). https:\/\/www.emcdda.europa.eu\/node\/13108_me"},{"key":"6451_CR11","volume-title":"European drug report 2022 : Trends and developments","author":"EMCDDA","year":"2022","unstructured":"EMCDDA (2022a) European drug report 2022 : Trends and developments. Publications Office of the European Union https:\/\/op.europa.eu\/en\/publication-detail\/-\/publication\/2d48883c-ed1f-11ec-a534-01aa75ed71a1\/language-en"},{"key":"6451_CR12","unstructured":"EMCDDA (2022b) European drug report 2022: trends and developments. https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2022_en"},{"key":"6451_CR13","doi-asserted-by":"publisher","unstructured":"EMCDDA (2022c) New psychoactive substances: 25 years of early warning and response in Europe \u2014 an update from the EU Early Warning System. https:\/\/doi.org\/10.2810\/396103","DOI":"10.2810\/396103"},{"key":"6451_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","volume":"41","author":"A Gillis","year":"2020","unstructured":"Gillis A, Kliewer A, Kelly E, Henderson G, Christie MJ, Schulz S, Canals M (2020) Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor. Trends Pharmacol Sci 41:947\u2013959. https:\/\/doi.org\/10.1016\/j.tips.2020.09.009","journal-title":"Trends Pharmacol Sci"},{"key":"6451_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41386-021-01227-8","volume":"47","author":"GC Glatfelter","year":"2022","unstructured":"Glatfelter GC, Partilla JS, Baumann MH (2022a) Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice. Neuropsychopharmacology 47:924\u2013932. https:\/\/doi.org\/10.1038\/s41386-021-01227-8","journal-title":"Neuropsychopharmacology"},{"key":"6451_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/acsptsci.2c00177","volume":"5","author":"GC Glatfelter","year":"2022","unstructured":"Glatfelter GC, Pottie E, Partilla JS, Sherwood AM, Kaylo K, Pham DNK, Naeem M, Sammeta VR, DeBoer S, Golen JA, Hulley EB, Stove CP, Chadeayne AR, Manke DR, Baumann MH (2022b) Structure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice. ACS Pharmacol Transl Sci 5:1181\u20131196. https:\/\/doi.org\/10.1021\/acsptsci.2c00177","journal-title":"ACS Pharmacol Transl Sci"},{"key":"6451_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF02161117","volume":"13","author":"F Gross","year":"1957","unstructured":"Gross F, Turrian H (1957) Benzimidazole derivatives with strong analgesic effects. Experientia 13:401\u2013403. https:\/\/doi.org\/10.1007\/BF02161117","journal-title":"Experientia"},{"key":"6451_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11419-022-00624-y","volume":"40","author":"K Hasegawa","year":"2022","unstructured":"Hasegawa K, Minakata K, Suzuki M, Suzuki O (2022) Non-fentanyl-derived synthetic opioids emerging during recent years. Forensic Toxicol 40:234\u2013243. https:\/\/doi.org\/10.1007\/s11419-022-00624-y","journal-title":"Forensic Toxicol"},{"key":"6451_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/BF02161116","volume":"13","author":"A Hunger","year":"1957","unstructured":"Hunger A, Kebrle J, Rossi A, Hoffmann K (1957) Synthesis of analgesically active benzimidazole derivatives with basic substitutions. Experientia 13:400\u2013401. https:\/\/doi.org\/10.1007\/BF02161116","journal-title":"Experientia"},{"key":"6451_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/hlca.19600430412","volume":"43","author":"A Hunger","year":"1960","unstructured":"Hunger A, Kebrle J, Rossi A, Hoffmann K (1960a) Benzimidazol-Derivate und verwandte Heterocyclen III. Synthese von 1-Aminoalkyl-2-nenzyl-nitro-benzimidazolen. Helvetica Chimica Acta 43:1032\u20131046. https:\/\/doi.org\/10.1002\/hlca.19600430412","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/hlca.19600430634","volume":"43","author":"A Hunger","year":"1960","unstructured":"Hunger A, Kebrle J, Rossi A, Hoffmann K (1960b) Benzimidazol-Derivate und verwandte Heterocyclen VI. Synthese von Phenyl-[1-aminoalkyl-benzimidazolyl-(2)]-essigs\u00e4ure-estern und -amiden. Helvetica Chimica Acta 43:1727\u20131733. https:\/\/doi.org\/10.1002\/hlca.19600430634","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/hlca.19600430323","volume":"43","author":"A Hunger","year":"1960","unstructured":"Hunger A, Kebrle J, Rossi A, Hoffmann K (1960c) Benzimidazol-Derivate und verwandte Heterocyclen. II. Synthese von 1-Aminoalkyl-2-benzyl-benzimidazolen. Helvetica Chimica Acta 43:800\u2013809. https:\/\/doi.org\/10.1002\/hlca.19600430323","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/hlca.19610440513","volume":"44","author":"A Hunger","year":"1961","unstructured":"Hunger A, Kebrle J, Rossi A, Hoffmann K (1961) Benzimidazol-Derivate und verwandte Heterocyclen VII. Synthese neuer 2-Amino-benzimidazole. Helvetica Chimica Acta 44:1273\u20131282. https:\/\/doi.org\/10.1002\/hlca.19610440513","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR24","first-page":"466","volume":"81","author":"A Jacobson","year":"1988","unstructured":"Jacobson A (1988) Biological evaluation of compounds for their physical dependence potential and abuse liability. XI. Drug testing program of the Committee on Problems of Drug Dependence, Inc. (1987). NIDA Res Monogr 81:466\u2013484","journal-title":"NIDA Res Monogr"},{"key":"6451_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/dta.3415","volume":"15","author":"T Kanamori","year":"2023","unstructured":"Kanamori T, Okada Y, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, Iwata YT (2023) Analysis of highly potent synthetic opioid nitazene analogs and their positional isomers. Drug Test Anal 15:449\u2013457. https:\/\/doi.org\/10.1002\/dta.3415","journal-title":"Drug Test Anal"},{"key":"6451_CR26","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1111\/bph.15004","volume":"177","author":"A Kliewer","year":"2020","unstructured":"Kliewer A, Gillis A, Hill R, Schmiedel F, Bailey C, Kelly E, Henderson G, Christie MJ, Schulz S (2020) Morphine-induced respiratory depression is independent of beta-arrestin2 signalling. Br J Pharmacol 177:2923\u20132931. https:\/\/doi.org\/10.1111\/bph.15004","journal-title":"Br J Pharmacol"},{"key":"6451_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","volume":"10","author":"A Kliewer","year":"2019","unstructured":"Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S (2019) Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun 10:367. https:\/\/doi.org\/10.1038\/s41467-018-08162-1","journal-title":"Nat Commun"},{"key":"6451_CR28","unstructured":"Krotulski A, Papsun D, Fogarty MF, Nelson L, Logan BK (2019) Potent synthetic opioid - isotonitazene - recently identified in the Midwestern United States. https:\/\/www.cfsre.org\/nps-discovery\/public-alerts\/potent-synthetic-opioid-isotonitazene-recently-identified-in-the-midwestern-united-states"},{"key":"6451_CR29","volume-title":"2022 Q1 NPS Opioid Trend Report","author":"A Krotulski","year":"2022","unstructured":"Krotulski A, Walton SE, Mohr ALA, Logan BK (2022a) 2022 Q1 NPS Opioid Trend Report. https:\/\/www.cfsre.org\/images\/trendreports\/2022-Q1-NPS-Opioids-Trend-Report.pdf"},{"key":"6451_CR30","unstructured":"Krotulski A, Walton SE, Mohr ALA, Logan BK (2022b) 2022 Q2 NPS Opioid Trend Report. https:\/\/www.cfsre.org\/images\/trendreports\/2022-Q2-NPS-Opioids-Trend-Report.pdf"},{"key":"6451_CR31","unstructured":"Krotulski A, Walton SE, Mohr ALA, Logan BK (2022c) 2022 Q3 NPS Opioid Trend Report. https:\/\/www.cfsre.org\/images\/trendreports\/2022-Q3-NPS-Opioids-Trend-Report.pdf"},{"key":"6451_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/jat\/bkaa016","volume":"44","author":"AJ Krotulski","year":"2020","unstructured":"Krotulski AJ, Papsun DM, Kacinko SL, Logan BK (2020) Isotonitazene quantitation and metabolite discovery in authentic forensic casework. J Anal Toxicol 44:521\u2013530. https:\/\/doi.org\/10.1093\/jat\/bkaa016","journal-title":"J Anal Toxicol"},{"key":"6451_CR33","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1021\/acs.jmedchem.1c01967","volume":"65","author":"JC Lee","year":"2022","unstructured":"Lee JC, Park H, Eubanks LM, Ellis B, Zhou B, Janda KD (2022) A vaccine against benzimidazole-derived new psychoactive substances that are more potent than fentanyl. J Med Chem 65:2522\u20132531. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01967","journal-title":"J Med Chem"},{"key":"6451_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107121","volume":"26","author":"NJ Malcolm","year":"2023","unstructured":"Malcolm NJ, Palkovic B, Sprague DJ, Calkins MM, Lanham JK, Halberstadt AL, Stucke AG, McCorvy JD (2023) Mu-opioid receptor selective superagonists produce prolonged respiratory depression. iScience 26:107121. https:\/\/doi.org\/10.1016\/j.isci.2023.107121","journal-title":"iScience"},{"key":"6451_CR35","volume-title":"Hamilton\u2019s Pharmacopoeia","author":"H Morris","year":"2009","unstructured":"Morris H (2009) Synthetic opioids: the most addictive drugs in the world. In: Hamilton\u2019s Pharmacopoeia. Hamilton's Pharmacopeia, Vice News https:\/\/www.vice.com\/en\/article\/9bdymy\/hamiltons-pharmacopeia-804-v16n4"},{"key":"6451_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110686","volume":"320","author":"F Mueller","year":"2021","unstructured":"Mueller F, Bogdal C, Pfeiffer B, Andrello L, Ceschi A, Thomas A, Grata E (2021) Isotonitazene: Fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland. Forensic Sci Int 320:110686. https:\/\/doi.org\/10.1016\/j.forsciint.2021.110686","journal-title":"Forensic Sci Int"},{"key":"6451_CR37","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","volume":"70","author":"J O'Donnell","year":"2021","unstructured":"O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J (2021) Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls - United States, 2019-2020. MMWR Morbidity and mortality weekly report 70:1740\u20131746. https:\/\/doi.org\/10.15585\/mmwr.mm7050e3","journal-title":"MMWR Morbidity and mortality weekly report"},{"key":"6451_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","volume":"43","author":"DM Papsun","year":"2022","unstructured":"Papsun DM, Krotulski AJ, Logan BK (2022) Proliferation of novel synthetic opioids in postmortem investigations after core-structure scheduling for fentanyl-related substances. Am J Forensic Med Pathol 43:315\u2013327. https:\/\/doi.org\/10.1097\/PAF.0000000000000787","journal-title":"Am J Forensic Med Pathol"},{"key":"6451_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","volume":"11","author":"MP Prekupec","year":"2017","unstructured":"Prekupec MP, Mansky PA, Baumann MH (2017) Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 11:256\u2013265. https:\/\/doi.org\/10.1097\/ADM.0000000000000324","journal-title":"J Addict Med"},{"key":"6451_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/jpet.105.087254","volume":"314","author":"KM Raehal","year":"2005","unstructured":"Raehal KM, Walker JK, Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195\u20131201. https:\/\/doi.org\/10.1124\/jpet.105.087254","journal-title":"J Pharmacol Exp Ther"},{"key":"6451_CR41","unstructured":"RAND Corporation (2022) Commission on combating synthetic opioid trafficking: final report."},{"key":"6451_CR42","unstructured":"Reavy P (2003) Utah case of potent drug is U.S. first. Deseret News. https:\/\/www.deseret.com\/2003\/6\/3\/19726293\/utah-case-of-potent-drug-is-u-s-first"},{"key":"6451_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1021\/acs.jcim.0c00890","volume":"61","author":"A Ricarte","year":"2021","unstructured":"Ricarte A, Dalton JAR, Giraldo J (2021) Structural assessment of agonist efficacy in the mu-opioid receptor: Morphine and fentanyl elicit different activation patterns. J Chem Inf Model 61:1251\u20131274. https:\/\/doi.org\/10.1021\/acs.jcim.0c00890","journal-title":"J Chem Inf Model"},{"key":"6451_CR44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/hlca.19600430515","volume":"43","author":"A Rossi","year":"1960","unstructured":"Rossi A, Hunger A, Kebrle J, Hoffmann K (1960a) Benzimidazol-Derivate und verwandte Heterocyclen V. Die Kondensation von o-Phenylendiamin mit aliphatischen und alicyclischen ?-Ketoestern. Helvetica Chimica Acta 43:1298\u20131313. https:\/\/doi.org\/10.1002\/hlca.19600430515","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR45","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/hlca.19600430413","volume":"43","author":"A Rossi","year":"1960","unstructured":"Rossi A, Hunger A, Kebrle J, Hoffmann K (1960b) Benzimidazol-Derivate und verwandte Heterocyclen. IV. Die Kondensation von o-Phenylendiamin mit ?-Aryl- und ?-Aryl-acetessigester. Helvetica Chimica Acta 43:1046\u20131056. https:\/\/doi.org\/10.1002\/hlca.19600430413","journal-title":"Helvetica Chimica Acta"},{"key":"6451_CR46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41386-021-01221-0","volume":"47","author":"D Rudin","year":"2022","unstructured":"Rudin D, McCorvy JD, Glatfelter GC, Luethi D, Szollosi D, Ljubisic T, Kavanagh PV, Dowling G, Holy M, Jaentsch K, Walther D, Brandt SD, Stockner T, Baumann MH, Halberstadt AL, Sitte HH (2022) (2-Aminopropyl)benzo[beta]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. Neuropsychopharmacology 47:914\u2013923. https:\/\/doi.org\/10.1038\/s41386-021-01221-0","journal-title":"Neuropsychopharmacology"},{"key":"6451_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1124\/jpet.121.001045","volume":"382","author":"EJ Santos","year":"2022","unstructured":"Santos EJ, Banks ML, Negus SS (2022) Role of efficacy as a determinant of locomotor activation by mu opioid receptor ligands in female and male mice. J Pharmacol Exp Ther 382:44\u201353. https:\/\/doi.org\/10.1124\/jpet.121.001045","journal-title":"J Pharmacol Exp Ther"},{"key":"6451_CR48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/ADM.0000000000000775","volume":"15","author":"CL Shover","year":"2021","unstructured":"Shover CL, Falasinnu TO, Freedman RB, Humphreys K (2021) Emerging characteristics of isotonitazene-involved overdose deaths: a case-control study. J Addict Med 15:429\u2013431. https:\/\/doi.org\/10.1097\/ADM.0000000000000775","journal-title":"J Addict Med"},{"key":"6451_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3109\/15563657508990076","volume":"8","author":"AT Shulgin","year":"1975","unstructured":"Shulgin AT (1975) Drugs of abuse in the future. Clin Toxicol 8:405\u2013456. https:\/\/doi.org\/10.3109\/15563657508990076","journal-title":"Clin Toxicol"},{"key":"6451_CR50","first-page":"239","volume":"32","author":"VI Sorokin","year":"1999","unstructured":"Sorokin VI (1999a) Etonitazene encountered in Moscow. Microgram 32:239\u2013244","journal-title":"Etonitazene encountered in Moscow. Microgram"},{"key":"6451_CR51","first-page":"20","volume":"9","author":"VI Sorokin","year":"1999","unstructured":"Sorokin VI (1999b) llegal synthesis of etonitazene. J Clandest Lab Invest Chem Assoc 9:20","journal-title":"J Clandest Lab Invest Chem Assoc"},{"key":"6451_CR52","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.bmc.2017.02.064","volume":"25","author":"PM Truong","year":"2017","unstructured":"Truong PM, Hassan SA, Lee YS, Kopajtic TA, Katz JL, Chadderdon AM, Traynor JR, Deschamps JR, Jacobson AE, Rice KC (2017) Modulation of opioid receptor affinity and efficacy via N-substitution of 9beta-hydroxy-5-(3-hydroxyphenyl)morphan: Synthesis and computer simulation study. Bioorg Med Chem 25:2406\u20132422. https:\/\/doi.org\/10.1016\/j.bmc.2017.02.064","journal-title":"Bioorg Med Chem"},{"key":"6451_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108195","volume":"177","author":"MT Truver","year":"2020","unstructured":"Truver MT, Smith CR, Garibay N, Kopajtic TA, Swortwood MJ, Baumann MH (2020) Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats. Neuropharmacology 177:108195. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108195","journal-title":"Neuropharmacology"},{"key":"6451_CR54","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","volume":"12","author":"I Ujvary","year":"2021","unstructured":"Ujvary I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R (2021) DARK classics in chemical neuroscience: etonitazene and related benzimidazoles. ACS Chem Neurosci 12:1072\u20131092. https:\/\/doi.org\/10.1021\/acschemneuro.1c00037","journal-title":"ACS Chem Neurosci"},{"key":"6451_CR55","volume-title":"Temporary reauthorization and study of the emergency scheduling of fentanyl analogues Act. S.3201 - 116th Congress","author":"United States Congress","year":"2020","unstructured":"United States Congress (2020) Temporary reauthorization and study of the emergency scheduling of fentanyl analogues Act. S.3201 - 116th Congress. https:\/\/www.congress.gov\/bill\/116th-congress\/senate-bill\/3201\/text"},{"key":"6451_CR56","unstructured":"UNODC (2020a) The growing complexity of the opioid crisis. Global SMART Update 24 https:\/\/www.unodc.org\/documents\/scientific\/Global_SMART-2020-Vol_24_web.pdf"},{"key":"6451_CR57","unstructured":"UNODC (2020b) United Nations Office on Drugs and Crime Early Warning Advisory Current NPS Threats - Volume III"},{"key":"6451_CR58","unstructured":"UNODC (2021) CND Decision on international control of isotonitazene enters into force. https:\/\/www.unodc.org\/LSS\/announcement\/Details\/65247392-26c7-4446-a2b6-270226103036"},{"key":"6451_CR59","unstructured":"UNODC (2022a) CND Decision on international control of brorphine and metonitazene enters into force. https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/a56e0bd9-0da5-4152-a34d-7cff7746bf50"},{"key":"6451_CR60","unstructured":"UNODC (2022b) Current NPS threats: Volume 5. https:\/\/www.unodc.org\/documents\/scientific\/Current_NPS_Threats_V.pdf"},{"key":"6451_CR61","unstructured":"UNODC (2023) May 2023 - UNODC: CND decision on international control of 2-methyl-AP-237, etazene, etonitazepyne, protonitazene enters into force. https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/89971a21-31d2-4f8a-8f28-e06f27c712ea"},{"key":"6451_CR62","doi-asserted-by":"publisher","unstructured":"Vandeputte MM, Krotulski AJ, Papsun DM, Logan BK, Stove CP (2021a) The rise and fall of isotonitazene and brorphine: Two recent stars in the synthetic opioid firmament. J Anal Toxicol. https:\/\/doi.org\/10.1093\/jat\/bkab082","DOI":"10.1093\/jat\/bkab082"},{"key":"6451_CR63","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","volume":"96","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Krotulski AJ, Walther D, Glatfelter GC, Papsun D, Walton SE, Logan BK, Baumann MH, Stove CP (2022a) Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Arch Toxicol 96:1845\u20131863. https:\/\/doi.org\/10.1007\/s00204-022-03276-4","journal-title":"Arch Toxicol"},{"key":"6451_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109939","volume":"249","author":"MM Vandeputte","year":"2023","unstructured":"Vandeputte MM, Tsai MM, Chen L, Glatfelter GC, Walther D, Stove CP, Shi L, Baumann MH (2023) Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide. Drug Alcohol Depend 249:109939. https:\/\/doi.org\/10.1016\/j.drugalcdep.2023.109939","journal-title":"Drug Alcohol Depend"},{"key":"6451_CR65","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","volume":"12","author":"MM Vandeputte","year":"2021","unstructured":"Vandeputte MM, Van Uytfanghe K, Layle NK, St Germaine DM, Iula DM, Stove CP (2021b) Synthesis, chemical characterization, and mu-opioid receptor activity assessment of the emerging group of \"Nitazene\" 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci 12:1241\u20131251. https:\/\/doi.org\/10.1021\/acschemneuro.1c00064","journal-title":"ACS Chem Neurosci"},{"key":"6451_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108161","volume":"235","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Vasudevan L, Stove CP (2022b) In vitro functional assays as a tool to study new synthetic opioids at the mu-opioid receptor: Potential, pitfalls and progress. Pharmacol Ther 235:108161. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108161","journal-title":"Pharmacol Ther"},{"key":"6451_CR67","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00204-022-03294-2","volume":"96","author":"MM Vandeputte","year":"2022","unstructured":"Vandeputte MM, Verougstraete N, Walther D, Glatfelter GC, Malfliet J, Baumann MH, Verstraete AG, Stove CP (2022c) First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass. Arch Toxicol 96:1865\u20131880. https:\/\/doi.org\/10.1007\/s00204-022-03294-2","journal-title":"Arch Toxicol"},{"key":"6451_CR68","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuropharm.2019.03.023","volume":"151","author":"NB Varshneya","year":"2019","unstructured":"Varshneya NB, Walentiny DM, Moisa LT, Walker TD, Akinfiresoye LR, Beardsley PM (2019) Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances. Neuropharmacology 151:171\u2013179. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.03.023","journal-title":"Neuropharmacology"},{"key":"6451_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173242","volume":"208","author":"NB Varshneya","year":"2021","unstructured":"Varshneya NB, Walentiny DM, Moisa LT, Walker TD, Akinfiresoye LR, Beardsley PM (2021) Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors. Pharmacol Biochem Behav 208:173242. https:\/\/doi.org\/10.1016\/j.pbb.2021.173242","journal-title":"Pharmacol Biochem Behav"},{"key":"6451_CR70","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00213-022-06292-5","volume":"240","author":"SE Walton","year":"2023","unstructured":"Walton SE, Krotulski AJ, Glatfelter GC, Walther D, Logan BK, Baumann MH (2023) Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats. Psychopharmacology (Berl) 240:185\u2013198. https:\/\/doi.org\/10.1007\/s00213-022-06292-5","journal-title":"Psychopharmacology (Berl)"},{"key":"6451_CR71","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/pr.112.005942","volume":"65","author":"JT Williams","year":"2013","unstructured":"Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013) Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223\u2013254. https:\/\/doi.org\/10.1124\/pr.112.005942","journal-title":"Pharmacol Rev"},{"key":"6451_CR72","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","volume":"185","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y, Wang Y, He B, He X, Zhou XE, Guo S, Rao Q, Yang J, Liu J, Zhou Q, Wang X, Liu M, Liu W, Jiang X, Yang D, Jiang H, Shen J, Melcher K, Chen H et al (2022) Molecular recognition of morphine and fentanyl by the human mu-opioid receptor. Cell 185:4361\u20134375 e19. https:\/\/doi.org\/10.1016\/j.cell.2022.09.041","journal-title":"Cell"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06451-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06451-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:02:27Z","timestamp":1699678947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06451-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6451"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06451-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}